Contraception, Thrombosis & Sickle Cell Disease: Considerations for Optimizing Comprehensive Care
This is a recorded version of Contraception, Thrombosis & Sickle Cell Disease: Considerations for Optimizing Comprehensive Care. This program was presented by Dr. Lydia Pecker, and was moderated by Dr. Andrea Roe. It took place on June 12, 2023. A copy of the recording may be obtained by contacting Katherine Cantu Anguiano, Manager of Education, via email at email@example.com.
Sickle cell disease (SCD) is a high-risk thrombophilia and in affected adults, thrombosis is associated with disease severity, high risk of recurrence and death. The increased pregnancy and menstruation-related morbidities of SCD and the potential teratogenicity of disease-modifying therapies make comprehensive care to address these risks, overall health, desire for fertility, and quality of life of great importance.
- Describe hormonal contraception considerations for people with sickle cell disease
- Discuss how to balance thrombotic risks associated with treatment on the one hand and high-risk pregnancy on the other
- Explain how progesterone only contraception is the preferred hormonal contraception for people with sickle cell disease
Lydia Pecker, MD
Director, Young Adult Clinic, Johns Hopkins Sickle Cell Center for Adults
Assistant Professor of Medicine
Assistant Professor of Gynecology and Obstetrics
Johns Hopkins Medicine
Andrea H. Roe, MD, MPH (Moderator)
Assistant Professor of Obstetrics and Gynecology